Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Tourmaline Bio Inc.
TRMLTourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Address: 27 West 24th Street, New York, NY, United States, 10010
Analytics
Objectif de Cours de WallStreet
58.33 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés TRML
Analyse des dividendes TRML
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
-3581 %Historique des dividendes TRML
Valorisation des titres TRML
financières TRML
Résultats | 2019 | Dynamique |